MX2017013333A - Metodo para purificacion de proteina. - Google Patents

Metodo para purificacion de proteina.

Info

Publication number
MX2017013333A
MX2017013333A MX2017013333A MX2017013333A MX2017013333A MX 2017013333 A MX2017013333 A MX 2017013333A MX 2017013333 A MX2017013333 A MX 2017013333A MX 2017013333 A MX2017013333 A MX 2017013333A MX 2017013333 A MX2017013333 A MX 2017013333A
Authority
MX
Mexico
Prior art keywords
monomeric
protein purification
human
provides
antibody
Prior art date
Application number
MX2017013333A
Other languages
English (en)
Inventor
Philip Heywood Sam
Barry Wild Gavin
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MX2017013333A publication Critical patent/MX2017013333A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona un método para recuperar un anticuerpo que contiene un dominio VH3 humano en forma monomérica. En particular, la presente invención proporciona un nuevo método que permite la recuperación de anticuerpos monoméricos que contienen el dominio VH3 humano a partir de una mezcla que contiene formas monoméricas y multiméricas del anticuerpo.
MX2017013333A 2015-04-22 2016-04-20 Metodo para purificacion de proteina. MX2017013333A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506868.7A GB201506868D0 (en) 2015-04-22 2015-04-22 Method for protein purification
PCT/EP2016/058774 WO2016169992A1 (en) 2015-04-22 2016-04-20 Method for protein purification

Publications (1)

Publication Number Publication Date
MX2017013333A true MX2017013333A (es) 2018-02-19

Family

ID=53299017

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013333A MX2017013333A (es) 2015-04-22 2016-04-20 Metodo para purificacion de proteina.

Country Status (19)

Country Link
US (2) US10927164B2 (es)
EP (1) EP3286205A1 (es)
JP (2) JP6866300B2 (es)
KR (1) KR102675400B1 (es)
CN (1) CN107636012B (es)
AR (1) AR104358A1 (es)
AU (1) AU2016251223B2 (es)
BR (1) BR112017022073A2 (es)
CA (1) CA2983057A1 (es)
CL (1) CL2017002614A1 (es)
CO (1) CO2017010631A2 (es)
EA (1) EA201792328A1 (es)
GB (1) GB201506868D0 (es)
IL (1) IL254883B (es)
MA (1) MA41941A (es)
MX (1) MX2017013333A (es)
MY (1) MY189854A (es)
SG (1) SG11201708256YA (es)
WO (1) WO2016169992A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9657055B2 (en) * 2011-11-30 2017-05-23 Ge Healthcare Bioprocess R&D Ab Affinity chromatography matrix
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
CN108085358A (zh) * 2018-02-08 2018-05-29 保定冀中药业有限公司 一种犬细小病毒单克隆抗体IgG2b-Fab片段的制备方法
EP4007771A1 (en) 2019-08-02 2022-06-08 UCB Biopharma SRL Methods for purifying antibodies
GB201919058D0 (en) * 2019-12-20 2020-02-05 Ucb Biopharma Sprl Multi-specific antibodies
BR112022011993A2 (pt) * 2019-12-26 2022-09-20 Abl Bio Inc Método para purificar peptídeo biologicamente ativo usando cromatografia de afinidade de proteína a
GB202109246D0 (en) * 2021-06-28 2021-08-11 Cytiva Bioprocess R & D Ab A method of separating bispecific antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
AU777005B2 (en) * 1999-05-15 2004-09-30 University Of California, San Diego Protein A based binding domains with desirable activities
CZ20031983A3 (cs) * 2000-12-29 2005-07-13 Savient Pharmaceuticals, Inc. Specifické protilátky pro selektivní léčbu rakoviny
JPWO2004087761A1 (ja) * 2003-03-31 2006-07-27 麒麟麦酒株式会社 ヒトモノクローナル抗体およびヒトポリクローナル抗体の精製
US20110144311A1 (en) * 2008-08-14 2011-06-16 Rebecca Chmielowski Methods for purifying antibodies using protein a affinity chromatography
JP5782385B2 (ja) 2009-02-17 2015-09-24 ユーシービー ファーマ ソシエテ アノニム ヒトｏｘ４０に対する特異性を有する抗体分子
CN103189390A (zh) * 2010-11-01 2013-07-03 帝斯曼知识产权资产管理有限公司 单一单元离子交换色谱抗体纯化
WO2012074463A1 (en) 2010-11-29 2012-06-07 Ge Healthcare Bio-Sciences Ab Affinity chromatography matrix
SG11201401649VA (en) 2011-11-11 2014-07-30 Ucb Pharma Sa Albumin binding antibodies and binding fragments thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
WO2013119966A2 (en) * 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
GB201223276D0 (en) 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
US9493563B2 (en) * 2013-11-04 2016-11-15 Glenmark Pharmaceuticals S.A. Production of T cell retargeting hetero-dimeric immunoglobulins
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506869D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method

Also Published As

Publication number Publication date
US10927164B2 (en) 2021-02-23
SG11201708256YA (en) 2017-11-29
IL254883B (en) 2021-09-30
EP3286205A1 (en) 2018-02-28
GB201506868D0 (en) 2015-06-03
AU2016251223A1 (en) 2017-10-26
US20210171609A1 (en) 2021-06-10
CN107636012A (zh) 2018-01-26
KR102675400B1 (ko) 2024-06-13
BR112017022073A2 (pt) 2018-08-14
JP2021066734A (ja) 2021-04-30
KR20170139131A (ko) 2017-12-18
CL2017002614A1 (es) 2018-04-27
AU2016251223B2 (en) 2021-12-09
AR104358A1 (es) 2017-07-12
CO2017010631A2 (es) 2018-01-05
WO2016169992A1 (en) 2016-10-27
US20180100007A1 (en) 2018-04-12
CN107636012B (zh) 2022-08-02
JP6866300B2 (ja) 2021-04-28
EA201792328A1 (ru) 2018-05-31
JP2018520089A (ja) 2018-07-26
IL254883A0 (en) 2017-12-31
CA2983057A1 (en) 2016-10-27
MA41941A (fr) 2018-02-28
MY189854A (en) 2022-03-14

Similar Documents

Publication Publication Date Title
MX2017013333A (es) Metodo para purificacion de proteina.
MX2022002364A (es) Anticuerpos anti-pd-l1.
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
ZA201608811B (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EP4249515A3 (en) Humanized or chimeric cd3 antibodies
NZ728688A (en) Anti-pd-1 antibodies
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MX2016016886A (es) Anticuerpos anti-axl.
IL248111A0 (en) A method to improve the solubility of protein and peptide by attaching to the immunoglobulin fc segment
IL285146A (en) Methods for purifying proteins involving FC
SG10201806481XA (en) Marburg monoclonal antibodies
PH12019502298A1 (en) Monoclonal antibody to pd-l1
SG10201807572PA (en) Robust antibody purification
IL255094A0 (en) A method for increasing the percentage of multimeric strains for a monomeric dsfv-fab antibody
MX2019013124A (es) Proteinas de fusion de inhibidor de tripsina urinaria (uti).
EP3092002A4 (en) Method of purifying monoclonal antibodies
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
EA201892231A1 (ru) Способ очистки белка
ZA201608812B (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
IL246881B (en) Method for purification of antibodies, antibody fragments or engineered variants thereof using specific anthraquinone dye-ligand structures